Related Experiment Video

Updated: Nov 17, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Capmatinib for non-small cell lung cancer

N Alzofon1, A Jimeno2

  • 1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

Drugs of Today (Barcelona, Spain : 1998)
|February 17, 2021
PubMed

Insights

Capmatinib effectively treats non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations, showing high response rates and a manageable safety profile. Further research is exploring its potential in other MET-dysregulated NSCLC cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular profiling has identified numerous oncogenic drivers in non-small cell lung cancer (NSCLC).
  • MET signaling is a promising target, but small-molecule inhibition has been challenging.
  • Capmatinib is a targeted therapy for NSCLC with MET exon 14 skipping mutations.

Purpose of the Study:

  • To review preclinical and clinical data supporting capmatinib's FDA approval.
  • To discuss the management of capmatinib-related toxicities.
  • To explore future research directions for capmatinib in MET-dysregulated NSCLC.

Main Methods:

  • Review of preclinical studies on MET inhibition.
  • Analysis of phase II clinical trial data for capmatinib efficacy and safety.
  • Examination of Food and Drug Administration (FDA) approval documentation.

Main Results:

  • Capmatinib demonstrated a 68% response rate as a first-line therapy in phase II trials.
  • The median duration of response to capmatinib was 12.6 months.
  • Capmatinib exhibited a manageable safety profile in treated patients.

Conclusions:

  • Capmatinib is an effective targeted therapy for NSCLC with MET exon 14 skipping mutations.
  • Ongoing studies are investigating capmatinib's efficacy in broader MET-dysregulated NSCLC populations.
  • Management of treatment-related toxicities is crucial for optimal capmatinib use.
Keywords:
CapmatinibHepatocyte growth factor (HGF; MET) inhibitorsINC-280INC-28060Non-small cell lung cancer (NSCLC) therapyOncolytic drugsTabrecta

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
312
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K